Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 3;27(17):5691.
doi: 10.3390/molecules27175691.

Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG

Affiliations

Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG

Lan Luo et al. Molecules. .

Abstract

Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic. However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear. Herein, two polysaccharides (BCG-1 and BCG-2) were purified and their structures were characterized. Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively. Herein, the mannan from BCG-PSN was first reported. Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection. These data suggest that BCG-1 and BCG-2 are very likely the active ingredients of BCG-PSN.

Keywords: active ingredients; glucan; immunomodulator; mannan; polysaccharide purification.

PubMed Disclaimer

Conflict of interest statement

The authors state no conflict of interest.

Figures

Figure 1
Figure 1
Purification and structural characterization of polysaccharides from BCG-PSN. (A) HPGPC profiles of BCG-PSN, BCG, BCG-1, BCG-2, and BCG-3; (B) UV absorption spectra of BCG-PSN, BCG, BCG-1, BCG-2, and BCG-3; (C) HPLC-DAD profiles of PMP derivatives of standard monosaccharides and the monosaccharides from polysaccharides; (D) FT-IR spectra of BCG-PSN, BCG, BCG-1, and BCG-2; (E) The TIC profile of PMAAs from the polysaccharide BCG-1; (F) The TIC profile of PMAAs from the polysaccharide BCG-2; noncarbohydrate signals are marked with ×.
Figure 1
Figure 1
Purification and structural characterization of polysaccharides from BCG-PSN. (A) HPGPC profiles of BCG-PSN, BCG, BCG-1, BCG-2, and BCG-3; (B) UV absorption spectra of BCG-PSN, BCG, BCG-1, BCG-2, and BCG-3; (C) HPLC-DAD profiles of PMP derivatives of standard monosaccharides and the monosaccharides from polysaccharides; (D) FT-IR spectra of BCG-PSN, BCG, BCG-1, and BCG-2; (E) The TIC profile of PMAAs from the polysaccharide BCG-1; (F) The TIC profile of PMAAs from the polysaccharide BCG-2; noncarbohydrate signals are marked with ×.
Figure 2
Figure 2
1H (A,B), 13C (C), COSY (D), HSQC-TOCSY (E), ROESY (F), HMBC (G) NMR spectra of BCG-1. Chemical shifts are relative to internal trimethylsilylpropionic acid sodium at 0 ppm. The letters A (maroon) and B (blue) represented 2,6-O-α-Manp (Residue A) and t-α-Manp (Residue B), respectively.
Figure 3
Figure 3
1H (A), 13C (B), COSY (C), TOCSY (D), HSQC-TOCSY (E), HMBC (F) NMR spectra of BCG-2. Chemical shifts are relative to external trimethylsilylpropionic acid sodium at 0 ppm. The letters A/B (maroon) represented →4)-α-Glc→1 (residue A)/→4,6)-α-Glc(1→ (residue B). The letters C (blue) represented t-α-Glc (1→ (residue C).
Figure 4
Figure 4
Proposed structures of BCG-1 (A) and BCG-2 (B) purified from BCG-PSN.
Figure 5
Figure 5
Effects of LPS, BCG-PSN, BCG-1, and BCG-2 on the production of NO (A) and mRNA expressions of iNOS (B) in RAW264.7 cells. LPS was at 100 ng/mL, BCG-PSN was at 87.5 µg/mL. * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. control, one-way ANOVA, Dunnett’s multiple comparisons test.
Figure 6
Figure 6
Effects of LPS, BCG-PSN, BCG-1, and BCG-2 on cytokines TNF-α (A), IL-6 (B), IL-1β (C), IL-10 (D) produced by the RAW 264.7 cells. LPS was at 100 ng/mL, BCG-PSN was at 87.5 µg/mL. * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. control, one-way ANOVA, Dunnett’s multiple comparisons test.
Figure 7
Figure 7
Effects of LPS, BCG-PSN, BCG-1, and BCG-2 on the mRNA expressions of TNF-α (A), IL-6 (B), IL-1β (C), IL-10 (D) in the RAW 264.7 cells. LPS was at 100 ng/mL, BCG-PSN was at 87.5 µg/mL. *** p < 0.001 vs. control, one-way ANOVA, Dunnett’s multiple comparisons test.

Similar articles

Cited by

References

    1. Sun J., Hou J., Li D., Liu Y., Hu N., Hao Y., Fu J., Hu Y., Shao Y. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant. Vaccine. 2013;31:472–479. doi: 10.1016/j.vaccine.2012.11.024. - DOI - PubMed
    1. Liu W., Wang H., Yu J., Liu Y., Lu W., Chai Y., Liu C., Pan C., Yao W., Gao X. Structure, chain conformation, and immunomodulatory activity of the polysaccharide purified from Bacillus Calmette Guerin formulation. Carbohydr. Polym. 2016;150:149–158. - PubMed
    1. Sharquie K.E., Hayani R.K. BCG as a new therapeutic and prophylactic agent in patients with severe oral aphthosis. Clin. Exp. Rheumatol. 2005;23:914. - PubMed
    1. Li N., Cao N., Niu Y.-D., Bai X.-H., Lu J., Sun Y., Yu M., Sun L.-X., Duan X.-S. Effects of the polysaccharide nucleic acid fraction of bacillus Calmette-Guérin on the production of interleukin-2 and interleukin-10 in the peripheral blood lymphocytes of patients with chronic idiopathic urticaria. Biomed. Rep. 2013;1:713–718. - PMC - PubMed
    1. Sloot S., Rashid O.M., Sarnaik A.A., Zager J.S. Developments in intralesional therapy for metastatic melanoma. Cancer Control. 2016;23:12–20. doi: 10.1177/107327481602300104. - DOI - PMC - PubMed

LinkOut - more resources